Is Novo Nordisk Stock a Falling Knife? Here’s What This Top Investor Thinks

Novo Nordisk (NVO) recently downgraded its 2025 sales growth forecast for its flagship GLP-1 drugs, Wegovy and Ozempic, from 13-21% to 8-14%, attributing the revision to increased competition and slower U.S. market expansion. This guidance cut, coinciding with a new CEO appointment, triggered a nearly 30% decline in NVO shares. However, despite the market reaction, some top investors and Wall Street analysts view the sell-off as an overreaction, maintaining a "Moderate Buy" consensus and citing the company's robust core business, continued growth prospects, and pipeline, including an oral semaglutide.

Analysis

Novo Nordisk (NVO) has experienced significant negative price action following a downward revision of its 2025 sales growth forecast. The company lowered its guidance from a range of 13-21% to 8-14%, citing persistent competition from compounded GLP-1s and a slower-than-anticipated expansion of the U.S. market for its flagship drugs, Wegovy and Ozempic. This announcement, coinciding with a planned CEO transition, triggered a near 30% drop in NVO's share price, extending its twelve-month decline to over 60%. Despite the market's severe reaction, a contrarian bullish sentiment is emerging from both analysts and specific investors. This view is predicated on the argument that the market has overreacted, as the company is still projecting robust growth, maintains a strong core business in diabetes and obesity care, and possesses growing cash flow. Furthermore, Wall Street consensus reflects a "Moderate Buy" rating with a 12-month average price target of $78.33, suggesting a potential upside of over 50%. A key future catalyst is the potential FDA approval of an oral semaglutide pill, which could significantly expand its customer base.

Key Decisions for Investors

• Investors with a long-term horizon might consider the greater than 60% year-over-year stock decline as a potential entry point, given that the company still forecasts 8-14% growth and Wall Street maintains a significant upside target.
• It is critical to monitor competitive dynamics, especially the market penetration of compounded GLP-1s and the pace of U.S. market expansion, as these are the stated headwinds behind the guidance cut.
• The progress of Novo Nordisk's oral semaglutide pill through the FDA review process is a key catalyst to watch, as a successful launch could materially improve the company's growth trajectory and competitive positioning.